Innoveren Scientific Inc. · OTC:IVRN
Innoveren Scientific — Medovex — Investor Presentation (May 2015)
18 slides from Innoveren Scientific's investor presentation, May 14, 2015
Slide 1: Medovex Investor Presentation May 2015
NASDAQ; MI May 2015
Slide 2: Forward-looking statements disclaimer
‘Th infin contain din his preertition has nan poopie sly forinfexSerl puapenes ands not an ff toby olor soleittion ofan fect by oll any even re Seri lb ose cyto designed p ntl inter te pp i sy tect seategy avd ay not bed end pon in ce fit pelvis plcemant mmmeceanenandeeliied nec, wich wl cenbin inp
Slide 3: Medovex emerging leader in aggregation of medical technologies
ZMEDOVEX Medovex™ Corp. is an emerging leader in the aggregation of medical and healthcare technologies. Along with our DenerveX™ device, we are building diversified portfolio of differentiated medical products via acquisition of companies that share our vision of improving the quality of patient ca
Slide 4: Medovex is an emerging leader in aggregation of medical and healthcare technologies
‘Modover is an emerging leader in the aggregation of medical and healthcare technologies. Along with our DenerveX System, we are building through acquisition a diversified portfolio of patented ‘Medtech assets focused on improving the quality of patient care hile possessing near term commercializati
Slide 5: DenerveX System and Streamline IV Suspension System
MEDOVEX Corporation will develop and acquire technologies that significantly improve patient quality of care and health care economics. Initially, we have focused on management of facet joint syndrome and intra-hospital patient transport. DenerveX System. Streamline IV Suspension System Less invasiv
Slide 6: Management and board affiliations
a —ENTRE 79S MEDIVATION MiMedx ENTREMpp = zt smith&nephew — Gystommmeric BEA ANDREWS Ry (3 DARA BiO Sciences’ @ MEDS Seiattific & ponic Golunenalohaen Hie
Slide 7: Market growth by commercializing medical technologies
MEDOVEX will achieve market growth by commercializing medical technologies that will ) _ significantly improve the quality of patient care. = 4 DenerveX System growth plan: Facet Joint Pain Relief Therapy Complete the development of the DenerveX System. + Gain CE marking and launch successfully in t
Slide 8: Facet joint syndrome
| + Facet joint syndrome (1JS) is a condition in hich the joints in the back of the spine degenerate and subsequently cause pain. + Bach joint has a rich supply of tiny nerve fibers that provide a painful stimulus when the joint is injured or irritated. * When facet joints become wom or tom, the car
Slide 9: Potential Market Opportunity and Key Market Drivers
pr Zt Potential Market Opportunity Key Market Drivers | DenerveX System | + Key unmet need clinically | + Providersand patients are looking fora more effective, | longer lasting pain relief solution RF ablation and FS injections are temporary (Streamline IV Suspension System | - “avg shovoge liom ow
Slide 10: Current Treatment Options
Current Treatment Options Spinal Injections RF (Rhizotomy) Facet Ijections Treatment Effectiveness: Temporary Treatment Effectiveness: Temporary
Slide 11: DenerveX Device and Pro-40 Power Generator
* Consists of tvo procedures combined into one device * Provides for a longer lasting treatment solution © Itisasingle use medical device Less invasive, minimal recovery time versus surgery © Offers potential savings to the health care system © Power Generator precisely matched with device for effec
Slide 12: DenerveX System Solution
Temporary Treatments Long Term Treatment DenerveX System Solution
Slide 13: Clinical efficacy of the DenerveX Device concept
+ The clinical efficacy of the DenerveX Device concepthas been demonstrated via a study of 174 patients with three to six year follow up. * The patients were treated using a two-step procedure of facet joint eapsular tissue removal and RF Ablation + The DenerveX Device from Medovex will provide a lo
Slide 14: Medovex has acquired Streamline
MEDOVEX corporation has acquired Streamline, a Minneapolis based medical technology company that develops and manufactures an intrahospital transport systema for patient equipment that helps reduce costs and increases safety in hospitals + Supports multiple pieces of patient medical equipment + Auto
Slide 15: The Problem / The Solution
The Problem The Solution ‘Traditional TV Pump and Equipment Approach. Streamline TV Suspension System Approach Safe Easy Efficient + Inefficient use of staff - Pulling nursing and other staff away from patients to help move equipment + Bloodstream infections related to this problem - 250,000 annuall
Slide 16: Unsafe
» Unsafe Medical equipment has become 7 . Likelihood of IV line disruption bigger and more cumbersome and _Limited available staff for Gsm supiteart: elite) snd the supporting base of equipment —_transport- right now it takes finardalonsietorhesptal has not kept pace. as many as 4 people or more to
Slide 17: Medovex Corporation
Medovex Corporation NASDAQ: MDVX Founded by Steve Gorlin (Entremed, Medicis, Medivation, MiMedx) + First developmental product Co-Developed by Dr. Scott Haufe and Dr. James Andrews (world renowned orthopedic surgeon) + Experienced and proven management team and board of directors + Strong balance sh
Slide 18: Medovex Corp. contact
i Medovex Corp. | 8729 Hardee Avenue | Atlanta, GA 30341 Phone: 844-633-6839 www Investor Contact Jason Assad ze